LGND News and Press, Ligand Pharmaceuticals Incorporated From 08/10/20

Ligand Pharmaceuticals (NASDAQ: LGND ) has agreed to acquire Pfenex (NYSEMKT: PFNX ) at $12/share, equivalent to $438M in equity value, representing a 57% premium to Pfenex’s last close price of $7.66 on August 10. More news on: Ligand Pharmaceuticals Incorporated, Pfenex Inc....

Expands Ligand’s industry-leading technology offerings by adding a proprietary protein expression technology platform Business expected to be earnings accretive in 2021 and to contribute substantial annual royalty revenue and cash flow going forward Ligand Pharmaceut...

A Phase 3 clinical trial evaluating CStone Pharmaceuticals' ( OTCPK:CSPHF ) PD-L1 inhibitor CS1001 for the first-line treatment of metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC) met the primary endpoin t of progression-free survival (PFS). More news on: CSTONE ...

CS1001 is the first anti-PD-L1 mAb to demonstrate overwhelming efficacy as First Line treatment of Stage IV squamous and non-squamous NSCLC in a randomized, double-blind Phase 3 trial CS1001 combined with chemotherapy had a statistically significant prolongation of progression-free ...

Ligand Pharmaceuticals Incorporated (LGND) Q2 2020 Earnings Conference Call August 03, 2020 08:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance & Chief Financial Office...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2020 Q2 earnings Read more ...

Raises 2020 Financial Guidance Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program...

Source: Reddit Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the confere...

Eli Lilly ( LLY +1.3% ) will collaborate with privately held Sermonix in an open-label Phase 2 clinical trial, ELAINE 2 , evaluating the combination of Verzenio (abemaciclib) and the latter's lead drug lasofoxifene in pre- and postmenopausal women with locally advanced/metastatic ER+/HE...